Trials / Unknown
UnknownNCT04730414
Full Spectrum Hemp Observational Study
Acne Vulgaris Blemish Full Spectrum Hemp Observational Study
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 50 (estimated)
- Sponsor
- Charlotte's Web, Inc · Industry
- Sex
- All
- Age
- 13 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
In westernized societies, acne vulgaris is nearly a universal skin disease afflicting 79% to 95% of the adolescent population; older than 25 years - 40% to 54% have facial blemishes and persists into middle age in 12% of women and 3% of men. Standard treatment modalities present with high risk morbidities. Charlotte's Web hemp blemish product is predicted to significantly reduce the risks mentioned above, while improving efficacy as well as imparting other skin benefits.
Detailed description
Charlotte's Web Full spectrum hemp blemish product will contain a mere 0.018% THC and will therefor not impart a psychotic affect. Hemp has been shown to be well tolerated in humans and has a very acceptable dosage, efficacy and safety profile when topically applied. The FDA has labeled hemp as Generally Regarded As Safe (GRAS) and as such reduces the risk of severe adverse reactions to the subject. Benefits of hemp blemish 'cream" is that it has been formulated in such a way as to promote natural skin balance, and may eliminate skin dryness, inflammation, hyperpigmentation, and scaring. The primary objective and endpoint of the study is to obtain total eradication of the blemish eruptions. The secondary objective and endpoints is the continued use of the hemp product will continue to prevent further blemish eruptions and provide other skin benefits especially reducing the propensity to scar.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Full-spectrum hemp (0.018% THC) | Topical Application |
Timeline
- Start date
- 2021-02-01
- Primary completion
- 2021-12-01
- Completion
- 2021-12-01
- First posted
- 2021-01-29
- Last updated
- 2021-02-01
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04730414. Inclusion in this directory is not an endorsement.